Enhancement of Hormone Activity by Monoclonal Antibodies

  • R. Bomford
  • R. Aston
Part of the NATO ASI Series book series (NSSA, volume 199)


The exploitation of genetic engineering technology has made available many protein hormones and mediators for clinical application in man; however, it is becoming progressively apparent that some of these recombinant molecules (e.g. TNF, IL-1, IL-2) retain high levels of toxicity in vivo. As a result of such observations, there is increasing interest in ways of improving the biological half-life and specificity of potential therapeutic agents. At the same time, it is also becoming apparent that many hormones/ mediators recognise several receptor subtypes distinguished by properties such as structure, affinity, specificity and tissue origin. It is probable that the different cellular receptors for hormones have evolved in order to provide an additional step in the complex regulatory process leading to a physiological response. Recent evidence also suggests some cellular receptors are released into the circulation in order to act as “carrier” proteins for hormones. Whether this effect is important to protect the relevant hormone from degradation or to provide a more optimal delivery and function is as yet unclear.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abel-Meguid, S.S., Shieh, H-S., Smith, W.W., Dayringer, H.E., Violand, B.N. and Bentle, L.A., 1987, Three dimensional structure of a genetically engineered variant of porcine growth hormone, Pr oc. Nat I.Acad. Sci., USA, 84:6434.CrossRefGoogle Scholar
  2. Aston, R., Holder, A.T., Preece, M.A. and Ivanyl, J., 1986, Potentiation of the somatogenic and lactogenic activity of human growth hormone with monoclonal antibodies, J.Endocrinol., 110:381.CrossRefGoogle Scholar
  3. Aston, R., Holder, A.T., Ivanyi, J. and Bomford, R., 1987, Enhancement of bovine growth hormone activity in vivo by monoclonal antibodies, Molec.Immunol., 24:143.CrossRefGoogle Scholar
  4. Aston, R., Cowden, W.B. and Ada, G.L., 1989, Antibody-mediated enhancement of hormone activity, Molec.Immunol., 26:435.CrossRefGoogle Scholar
  5. Aston, R., Rath jen, D.A., Holder, A.T., Bender, V., Trigg, T.E., Cowan, K., Edwards, J.A. and Cowden, W.B., 1990, Antigenic structure of bovine growth hormone: location of a growth enhancing region, (submitted for publication).Google Scholar
  6. Beutler, B., Milsark, I.W. and Cerami, A.C., 1985, Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science, 229:869.CrossRefPubMedGoogle Scholar
  7. Bomford, R. and Aston, R., 1990, Enhancement of bovine growth hormone activity by anti-peptide auto-antibody, J.Endocrinol., in press.Google Scholar
  8. Cadman, H.F. and Wallis, M., 1981, An investigation of the sites that bind human somatotropin (growth hormone) in the liver of the pregnant rabbit, Biochem.J., 198:605.CrossRefPubMedGoogle Scholar
  9. Clark, R.G., Jansson, J-O., Isakson, O. and Robinson, I.C.A.F., 1985, Intravenous growth hormone: growth responses to patterned infusion in the hophysectionized rat, J.Endocrinol., 104:53.CrossRefGoogle Scholar
  10. Frackelton, A.R. and Rotman, B., 1980, Functional diversity of antibodies elicited by bacterial beta-D-galactosidase, J.Biol.Chem., 225:5286.Google Scholar
  11. Holder, A.T., Wallis, M., Biggs, P. and Preece, M.A., 1980, Effects of growth hormone, prolactin and thyroxine on body weight, somatomedin- like activity and in vivo sulphation of cartilage in hypopituitary dwarf mice, J.Endocrinol., 85:35.CrossRefGoogle Scholar
  12. Holder, A.T., Aston, R., Preece, M.A. and Ivanyi, J., 1985, Monoclonal anti- body-mediated enhancement of growth hormone activity in vivo, J.Endocrinol., 107:59.CrossRefGoogle Scholar
  13. Holder, A.T., Aston, R., Rest, J.R., Hill, D.J., Patel, N. and Ivanyi, J., 1987, Monoclonal antibodies can enhance the biological activity of thyrotrophin. Endocrinology., 120:567.CrossRefGoogle Scholar
  14. Jones, W.R., Bradley, J., Judd, S.J., Denholm, E.H., Ing, R.M.Y., Mueller, U.W., Powell, J., Griffin, P.D. and Stevens, V.C., 1988, Phase I clinical trial of a World Health Organisation birth control vaccine, Lancet, i:1295.CrossRefGoogle Scholar
  15. Miller, W.L., and Eberhardt, N.L., 1983, Structure and evolution of the growth hormone gene family. Endocrine Rev., 4:97.CrossRefGoogle Scholar
  16. Schreiber, R.D., Hicks, L.J., Celada, A., Buchmeier, N.A. and Gray, P.W., 1985, Monoclonal antibodies to murine gamma-interferon which differentially modulate macrophage activation and antiviral activity, J.Immunol., 134:1609.Google Scholar
  17. Shechter, Y., Chang, K.J., Jacobs, S. and Cuatrecasas, P., 1979, Modulation of binding and bioactivity of insulin by anti-insulin antibody: relation to possible role of receptor self aggregation in hormone action, Proc.Natl.Acad.Sci.USA, 76:2720.CrossRefPubMedGoogle Scholar
  18. Smith, W.C., Linzer, D.I. and Talamantes, F., 1988, Detection of two growth hormone receptor mRNAs and primary translation products in the mouse, Proc.Natl.Acad. Sci.USA, 85:9576.CrossRefPubMedGoogle Scholar
  19. Wallis, M., Daniels, M., Ray, K.P., Cottingham, J.D. and Aston, R., 1987, Monoclonal antibodies to bovine growth hormone potentiate effects of the hormone on somatanoedin C levels and growth of hypophysectionized rats, Biochem.Biophys.Res.Comm., 149:187.CrossRefPubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • R. Bomford
    • 1
  • R. Aston
    • 1
    • 2
  1. 1.Wellcome BiotechnologyBeckenham, KentUK
  2. 2.Peptide Technology Ltd.Dee WhyAustralia

Personalised recommendations